Giuseppe Giannini

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/810672/publications.pdf

Version: 2024-02-01

151 papers	9,458 citations	57758 44 h-index	40979 93 g-index
156 all docs	156 docs citations	156 times ranked	15724 citing authors

#	Article	IF	Citations
1	RAS Mutation Conversion in Bevacizumab-Treated Metastatic Colorectal Cancer Patients: A Liquid Biopsy Based Study. Cancers, 2022, 14, 802.	3.7	8
2	Induction of Pro-Fibrotic CLIC4 in Dermal Fibroblasts by TGF-Î²/Wnt3a Is Mediated by GLI2 Upregulation. Cells, 2022, 11, 530.	4.1	5
3	An integrative in-silico analysis discloses a novel molecular subset of colorectal cancer possibly eligible for immune checkpoint immunotherapy. Biology Direct, 2022, 17, 10.	4.6	0
4	The Mechanism of Action of Biguanides: New Answers to a Complex Question. Cancers, 2022, 14, 3220.	3.7	14
5	Discovery of novel human lactate dehydrogenase inhibitors: Structure-based virtual screening studies and biological assessment. European Journal of Medicinal Chemistry, 2022, 240, 114605.	5.5	4
6	Downregulation of miRâ€326 and its host gene Î²â€arrestin1 induces proâ€survival activity of E2F1 and promotes medulloblastoma growth. Molecular Oncology, 2021, 15, 523-542.	4.6	8
7	Pharmacological targeting of the novel Î²-catenin chromatin-associated kinase p38Î± in colorectal cancer stem cell tumorspheres and organoids. Cell Death and Disease, 2021, 12, 316.	6.3	11
8	A multidisciplinary approach for the differential diagnosis between multiple primary lung adenocarcinomas and intrapulmonary metastases. Pathology Research and Practice, 2021, 220, 153387.	2.3	5
9	Specific Protein 1 and p53 Interplay Modulates the Expression of the KCTD-Containing Cullin3 Adaptor Suppressor of Hedgehog 2. Frontiers in Cell and Developmental Biology, 2021, 9, 638508.	3.7	5
10	PIK3CA somatic mutation in sinonasal teratocarcinosarcoma. Auris Nasus Larynx, 2021, 48, 530-534.	1.2	7
11	True conversions from RAS mutant to RAS wild-type in circulating tumor DNA from metastatic colorectal cancer patients as assessed by methylation and mutational signature. Cancer Letters, 2021, 507, 89-96.	7.2	10
12	Enzymatic Spermine Metabolites Induce Apoptosis Associated with Increase of p53, caspase-3 and miR-34a in Both Neuroblastoma Cells, SJNKP and the N-Myc-Amplified Form IMR5. Cells, 2021, 10, 1950.	4.1	9
13	Transcriptome of Male Breast Cancer Matched with Germline Profiling Reveals Novel Molecular Subtypes with Possible Clinical Relevance. Cancers, 2021, 13, 4515.	3.7	6
14	Translational control of polyamine metabolism by CNBP is required for Drosophila locomotor function. ELife, 2021, 10, .	6.0	10
15	A combination of PARP and CHK1 inhibitors efficiently antagonizes MYCN-driven tumors. Oncogene, 2021, 40, 6143-6152.	5.9	16
16	Comparison of Two Blood-Based Genotyping Tests to Investigate the KRAS G12C Mutation in Patients with Non-Small-Cell Lung Cancer at Failure of First-Line Treatments. Diagnostics, 2021, 11, 2196.	2.6	3
17	Association of Genomic Domains in BRCA1 and BRCA2 with Prostate Cancer Risk and Aggressiveness. Cancer Research, 2020, 80, 624-638.	0.9	39
18	Notch3 contributes to T-cell leukemia growth via regulation of the unfolded protein response. Oncogenesis, 2020, 9, 93.	4.9	13

#	Article	IF	Citations
19	Sulfonamide Inhibitors of Î²â€Catenin Signaling as Anticancer Agents with Different Output on câ€MYC. ChemMedChem, 2020, 15, 2264-2268.	3.2	5
20	Blockade of EIF5A hypusination limits colorectal cancer growth by inhibiting MYC elongation. Cell Death and Disease, 2020, 11, 1045.	6.3	39
21	A novel BRCA2 splice variant identified in a young woman. Molecular Genetics & Genomic Medicine, 2020, 8, e1513.	1.2	1
22	Nanotechnology-Based Strategies to Develop New Anticancer Therapies. Biomolecules, 2020, 10, 735.	4.0	32
23	Clinical Multigene Panel Sequencing Identifies Distinct Mutational Association Patterns in Metastatic Colorectal Cancer. Frontiers in Oncology, 2020, 10, 560.	2.8	12
24	Phenformin Inhibits Hedgehog-Dependent Tumor Growth through a Complex I-Independent Redox/Corepressor Module. Cell Reports, 2020, 30, 1735-1752.e7.	6.4	37
25	The RNA-Binding Ubiquitin Ligase MEX3A Affects Glioblastoma Tumorigenesis by Inducing Ubiquitylation and Degradation of RIG-I. Cancers, 2020, 12, 321.	3.7	46
26	Aged garlic extract and its constituent, Sâ€˜allylâ€˜Lâ€˜cysteine, induce the apoptosis of neuroblastoma cancer cells due to mitochondrial membrane depolarization. Experimental and Therapeutic Medicine, 2020, 19, 1511-1521.	1.8	12
27	Mitogen-activated kinase kinase kinase 1 inhibits hedgehog signaling and medulloblastoma growth through GLI1 phosphorylation. International Journal of Oncology, 2019, 54, 505-514.	3.3	19
28	ERAP1 promotes Hedgehog-dependent tumorigenesis by controlling USP47-mediated degradation of Î²TrCP. Nature Communications, 2019, 10, 3304.	12.8	35
29	KCTD15 inhibits the Hedgehog pathway in Medulloblastoma cells by increasing protein levels of the oncosuppressor KCASH2. Oncogenesis, 2019, 8, 64.	4.9	21
30	Kras/ADAM17-Dependent Jag1-ICD Reverse Signaling Sustains Colorectal Cancer Progression and Chemoresistance. Cancer Research, 2019, 79, 5575-5586.	0.9	24
31	A Simplified Genomic Profiling Approach Predicts Outcome in Metastatic Colorectal Cancer. Cancers, 2019, 11, 147.	3.7	15
32	Maize polyamine oxidase in the presence of spermine/spermidine induces the apoptosis of LoVo human colon adenocarcinoma cells. International Journal of Oncology, 2019, 54, 2080-2094.	3.3	12
33	Next-generation sequencing of BRCA1 and BRCA2 genes for rapid detection of germline mutations in hereditary breast/ovarian cancer. PeerJ, 2019, 7, e6661.	2.0	21
34	Polyamine Metabolism as a Therapeutic Target in
Hedgehog-Driven Basal Cell Carcinoma
and Medulloblastoma. Cells, 2019, 8, 150.	4.1	17
35	SMO-M2 mutation does not support cell-autonomous Hedgehog activity in cerebellar granule cell precursors. Scientific Reports, 2019, 9, 19623.	3.3	4
36	Why the Therapeutic Impact of RAS Mutation Clearance in Plasma ctDNA Deserves to Be Further Explored in Metastatic Colorectal Cancer. Frontiers in Oncology, 2019, 9, 1414.	2.8	7

#	Article	IF	Citations
37	Insight into genetic susceptibility to male breast cancer by multigene panel testing: Results from a multicenter study in Italy. International Journal of Cancer, 2019, 145, 390-400.	5.1	40
38	Drug Design and Synthesis of First in Class PDZ1 Targeting NHERF1 Inhibitors as Anticancer Agents. ACS Medicinal Chemistry Letters, 2019, 10, 499-503.	2.8	13
39	Transient Disappearance of RAS Mutant Clones in Plasma: A Counterintuitive Clinical Use of EGFR Inhibitors in RAS Mutant Metastatic Colorectal Cancer. Cancers, 2019, 11, 42.	3.7	44
40	Evaluation of CYP17A1 and CYP1B1 polymorphisms in male breast cancer risk. Endocrine Connections, 2019, 8, 1224-1229.	1.9	6
41	Identification of novel BRCA1 large genomic rearrangements by a computational algorithm of amplicon-based Next-Generation Sequencing data. PeerJ, 2019, 7, e7972.	2.0	2
42	Itch/Î²-arrestin2-dependent non-proteolytic ubiquitylation of SuFu controls Hedgehog signalling and medulloblastoma tumorigenesis. Nature Communications, 2018, 9, 976.	12.8	53
43	Evaluation of Polygenic Determinants of Non-Alcoholic Fatty Liver Disease (NAFLD) By a Candidate Genes Resequencing Strategy. Scientific Reports, 2018, 8, 3702.	3.3	59
44	Mutational spectrum in a worldwide study of 29,700 families withBRCA1orBRCA2mutations. Human Mutation, 2018, 39, 593-620.	2.5	224
45	Optimizing the identification of riskâ€relevant mutations by multigene panel testing in selected hereditary breast/ovarian cancer families. Cancer Medicine, 2018, 7, 46-55.	2.8	28
46	Targeting class <scp>I</scp> histone deacetylases by the novel small molecule inhibitor 4<scp>SC</scp>â€202 blocks oncogenic hedgehogâ€<scp>GLI</scp> signaling and overcomes smoothened inhibitor resistance. International Journal of Cancer, 2018, 142, 968-975.	5.1	39
47	The antioxidant, aged garlic extract, exerts cytotoxic effects on wild-type and multidrug-resistant human cancer cells by altering mitochondrial permeability. International Journal of Oncology, 2018, 53, 1257-1268.	3.3	10
48	MRE11 inhibition highlights a replication stress-dependent vulnerability of MYCN-driven tumors. Cell Death and Disease, 2018, 9, 895.	6.3	35
49	Effective treatment of a platinumâ€resistant cutaneous squamous cell carcinoma case by EGFR pathway inhibition. Molecular and Clinical Oncology, 2018, 9, 30-34.	1.0	13
50	Coexistence of three EGFR mutations in an NSCLC patient: A brief report. International Journal of Biological Markers, 2018, 33, 545-548.	1.8	7
51	Epigenetic siRNA and Chemical Screens Identify SETD8 Inhibition as a Therapeutic Strategy for p53 Activation in High-Risk Neuroblastoma. Cancer Cell, 2017, 31, 50-63.	16.8	79
52	Selective targeting of HDAC1/2 elicits anticancer effects through Gli1 acetylation in preclinical models of SHH Medulloblastoma. Scientific Reports, 2017, 7, 44079.	3.3	57
53	Obinutuzumab-mediated high-affinity ligation of FcÎ³RIIIA/CD16 primes NK cells for IFNÎ³ production. OncoImmunology, 2017, 6, e1290037.	4.6	39
54	The role of peroxiredoxins in cancer. Molecular and Clinical Oncology, 2017, 6, 139-153.	1.0	145

#	Article	IF	Citations
55	A Specific Mutational Signature Associated with DNA 8-Oxoguanine Persistence in MUTYH-defective Colorectal Cancer. EBioMedicine, 2017, 20, 39-49.	6.1	170
56	Wholeâ€exome sequencing and targeted gene sequencing provide insights into the role of PALB2 as a male breast cancer susceptibility gene. Cancer, 2017, 123, 210-218.	4.1	31
57	Î²-arrestin1-mediated acetylation of Gli1 regulates Hedgehog/Gli signaling and modulates self-renewal of SHH medulloblastoma cancer stem cells. BMC Cancer, 2017, 17, 488.	2.6	62
58	Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2. Breast Cancer Research, 2016, 18, 15.	5.0	88
59	Detection of ATM germline variants by the p53 mitotic centrosomal localization test in BRCA1/2-negative patients with early-onset breast cancer. Journal of Experimental and Clinical Cancer Research, 2016, 35, 135.	8.6	9
60	Translating Hedgehog in Cancer: Controlling Protein Synthesis. Trends in Molecular Medicine, 2016, 22, 851-862.	6.7	13
61	Inhibition of Hedgehog-dependent tumors and cancer stem cells by a newly identified naturally occurring chemotype. Cell Death and Disease, 2016, 7, e2376-e2376.	6.3	49
62	A MYCN-MRN complex axis controls replication stress for the safe expansion of neuroprogenitor cells. Molecular and Cellular Oncology, 2016, 3, e1079673.	0.7	9
63	The energy sensor AMPK regulates Hedgehog signaling in human cells through a unique Gli1 metabolic checkpoint. Oncotarget, 2016, 7, 9538-9549.	1.8	40
64	Gli1/ <scp>DNA</scp> interaction is a druggable target for Hedgehogâ€dependent tumors. EMBO Journal, 2015, 34, 200-217.	7.8	147
65	Novel and known genetic variants for male breast cancer risk at 8q24.21, 9p21.3, 11q13.3 and 14q24.1: Results from a multicenter study in Italy. European Journal of Cancer, 2015, 51, 2289-2295.	2.8	25
66	Digging a hole under Hedgehog: downstream inhibition as an emerging anticancer strategy. Biochimica Et Biophysica Acta: Reviews on Cancer, 2015, 1856, 62-72.	7.4	44
67	Validation of the Ion Torrent PGM sequencing for the prospective routine molecular diagnostic of colorectal cancer. Clinical Biochemistry, 2015, 48, 908-910.	1.9	30
68	Association of Type and Location ofBRCA1andBRCA2Mutations With Risk of Breast and Ovarian Cancer. JAMA - Journal of the American Medical Association, 2015, 313, 1347.	7.4	390
69	Direct Correlation Between Double K-RAS Mutation and Mucinous Carcinoma. A Case Report. Applied Immunohistochemistry and Molecular Morphology, 2015, 23, e4-e7.	1.2	0
70	Non-canonical Hedgehog/AMPK-Mediated Control of Polyamine Metabolism Supports Neuronal and Medulloblastoma Cell Growth. Developmental Cell, 2015, 35, 21-35.	7.0	62
71	Characterization of medulloblastoma in Fanconi Anemia: a novel mutation in the BRCA2 gene and SHH molecular subgroup. Biomarker Research, 2015, 3, 13.	6.8	28
72	Determination of Acetylation of the Gli Transcription Factors. Methods in Molecular Biology, 2015, 1322, 147-156.	0.9	3

#	Article	IF	Citations
73	Candidate Genetic Modifiers for Breast and Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 308-316.	2.5	22
74	MET Gene Amplification and MET Receptor Activation Are Not Sufficient to Predict Efficacy of Combined MET and EGFR Inhibitors in EGFR TKI-Resistant NSCLC Cells. PLoS ONE, 2015, 10, e0143333.	2.5	21
75	Vemurafenib and panitumumab combination tailored therapy in BRAF-mutated metastatic colorectal cancer. Cancer Biology and Therapy, 2014, 15, 826-831.	3.4	24
76	Circulating tumor cells. Cancer Biology and Therapy, 2014, 15, 496-503.	3.4	40
77	CNBP regulates wing development inDrosophila melanogasterby promoting IRES-dependent translation of dMyc. Cell Cycle, 2014, 13, 434-439.	2.6	17
78	Druggable glycolytic requirement for Hedgehog-dependent neuronal and medulloblastoma growth. Cell Cycle, 2014, 13, 3404-3413.	2.6	44
79	Novel and recurrent BRCA2 mutations in Italian breast/ovarian cancer families widen the ovarian cancer cluster region boundaries to exons 13 and 14. Breast Cancer Research and Treatment, 2014, 148, 629-635.	2.5	12
80	Associations of common breast cancer susceptibility alleles with risk of breast cancer subtypes in BRCA1 and BRCA2 mutation carriers. Breast Cancer Research, 2014, 16, 3416.	5.0	57
81	Targeted therapy against chemoresistant colorectal cancers: Inhibition of p38Î± modulates the effect of cisplatin in vitro and in vivo through the tumor suppressor FoxO3A. Cancer Letters, 2014, 344, 110-118.	7.2	45
82	Yin-Yang strands of PCAF/Hedgehog axis in cancer control. Trends in Molecular Medicine, 2014, 20, 416-418.	6.7	13
83	PRDX1 and PRDX6 are repressed in papillary thyroid carcinomas via BRAF V600E-dependent and -independent mechanisms. International Journal of Oncology, 2014, 44, 548-556.	3.3	27
84	The HMGA1 protoncogene frequently deregulated in cancer is a transcriptional target of E2F1. Molecular Carcinogenesis, 2013, 52, 526-534.	2.7	22
85	Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nature Genetics, 2013, 45, 371-384.	21.4	493
86	microRNA-17-92 cluster is a direct Nanog target and controls neural stem cell through Trp53inp1. EMBO Journal, 2013, 32, 2819-2832.	7.8	70
87	Metastatic colorectal cancer first-line treatment with bevacizumab: the impact of K-ras mutation. OncoTargets and Therapy, 2013, 6, 1761.	2.0	7
88	Gli2 Acetylation at Lysine 757 Regulates Hedgehog-Dependent Transcriptional Output by Preventing Its Promoter Occupancy. PLoS ONE, 2013, 8, e65718.	2.5	61
89	Molecular mechanisms of MYCN-dependent apoptosis and the MDM2â€“p53 pathway: an Achilleâ€™s heel to be exploited for the therapy of MYCN-amplified neuroblastoma. Frontiers in Oncology, 2012, 2, 141.	2.8	20
90	CCAAT/Enhancer-Binding Proteins Are Key Regulators of Human Type Two Deiodinase Expression in a Placenta Cell Line. Endocrinology, 2012, 153, 4030-4038.	2.8	6

#	Article	IF	Citations
91	Common Variants at the 19p13.1 and ZNF365 Loci Are Associated with ER Subtypes of Breast Cancer and Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. Cancer Epidemiology Biomarkers and Prevention, 2012, 21, 645-657.	2.5	47
92	Genome-wide association study identifies a common variant in RAD51B associated with male breast cancer risk. Nature Genetics, 2012, 44, 1182-1184.	21.4	99
93	Hedgehog/Gli Control by Ubiquitination/Acetylation Interplay. Vitamins and Hormones, 2012, 88, 211-227.	1.7	47
94	Galectin-3 Impairment of MYCN-Dependent Apoptosis-Sensitive Phenotype Is Antagonized by Nutlin-3 in Neuroblastoma Cells. PLoS ONE, 2012, 7, e49139.	2.5	22
95	Clinical and pathologic characteristics of BRCA-positive and BRCA-negative male breast cancer patients: results from a collaborative multicenter study in Italy. Breast Cancer Research and Treatment, 2012, 134, 411-418.	2.5	73
96	Identification and Characterization of KCASH2 and KCASH3, 2 Novel Cullin3 Adaptors Suppressing Histone Deacetylase and Hedgehog Activity in Medulloblastoma. Neoplasia, 2011, 13, 374-IN23.	5.3	82
97	Protected from the inside: Endogenous histone deacetylase inhibitors and the road to cancer. Biochimica Et Biophysica Acta: Reviews on Cancer, 2011, 1815, 241-252.	7.4	32
98	International distribution and age estimation of the Portuguese BRCA2 c.156_157insAlu founder mutation. Breast Cancer Research and Treatment, 2011, 127, 671-679.	2.5	27
99	The CASP8 rs3834129 polymorphism and breast cancer risk in BRCA1 mutation carriers. Breast Cancer Research and Treatment, 2011, 125, 855-860.	2.5	11
100	Common alleles at 6q25.1 and 1p11.2 are associated with breast cancer risk for BRCA1 and BRCA2 mutation carriers. Human Molecular Genetics, 2011, 20, 3304-3321.	2.9	68
101	MYCN Sensitizes Human Neuroblastoma to Apoptosis by HIPK2 Activation through a DNA Damage Response. Molecular Cancer Research, 2011, 9, 67-77.	3.4	30
102	HE4 in the Differential Diagnosis of a Pelvic Mass: A Case Report. International Journal of Molecular Sciences, 2011, 12, 627-632.	4.1	9
103	PALB2 mutations in male breast cancer: a population-based study in Central Italy. Breast Cancer Research and Treatment, 2010, 122, 299-301.	2.5	44
104	The BRCAPRO 5.0 model is a useful tool in genetic counseling and clinical management of male breast cancer cases. European Journal of Human Genetics, 2010, 18, 856-858.	2.8	16
105	Hedgehog controls neural stem cells through p53-independent regulation of Nanog. EMBO Journal, 2010, 29, 2646-2658.	7.8	208
106	Histone deacetylase and Cullin3â€“RENKCTD11 ubiquitin ligase interplay regulates Hedgehog signalling through Gli acetylation. Nature Cell Biology, 2010, 12, 132-142.	10.3	292
107	NF-ÎºB, and not MYCN, Regulates MHC Class I and Endoplasmic Reticulum Aminopeptidases in Human Neuroblastoma Cells. Cancer Research, 2010, 70, 916-924.	0.9	65
108	Turning off the switch in medulloblastoma: The inhibitory acetylation of an oncogene. Cell Cycle, 2010, 9, 2047-2048.	2.6	7

#	Article	IF	Citations
109	The coactivator CRTC1 promotes cell proliferation and transformation via AP-1. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 1445-1450.	7.1	59
110	MiRâ€128 upâ€regulation inhibits Reelin and DCX expression and reduces neuroblastoma cell motility and invasiveness. FASEB Journal, 2009, 23, 4276-4287.	0.5	148
111	BRCA1/BRCA2 mutation status and clinical-pathologic features of 108 male breast cancer cases from Tuscany: a population-based study in central Italy. Breast Cancer Research and Treatment, 2009, 116, 577-586.	2.5	53
112	TORCs/CRTCs: More than mere coincidence. Cell Cycle, 2009, 8, 959-964.	2.6	11
113	BRCA1/BRCA2 rearrangements and CHEK2 common mutations are infrequent in Italian male breast cancer cases. Breast Cancer Research and Treatment, 2008, 110, 161-167.	2.5	42
114	Human Papilloma Virus-Dependent HMGA1 Expression Is a Relevant Step in Cervical Carcinogenesis. Neoplasia, 2008, 10, 773-781.	5.3	15
115	An Integrated Approach Identifies Nhlh1 and Insm1 as Sonic Hedgehog-regulated Genes in Developing Cerebellum and Medulloblastoma. Neoplasia, 2008, 10, 89-IN36.	5.3	48
116	Clinical Classification of BRCA1 DNA Missense Variants: H1686Q Is a Novel Pathogenic Mutation Occurring in the Ontogenetically Invariant THV Motif of the N-Terminal BRCT Domain. Journal of Clinical Oncology, 2008, 26, 4212-4214.	1.6	15
117	Activation of Thyroid Hormone Is Transcriptionally Regulated by Epidermal Growth Factor in Human Placenta-Derived JEG3 Cells. Endocrinology, 2008, 149, 695-702.	2.8	17
118	Does the Search for Large Genomic Rearrangements Impact BRCAPRO Carrier Prediction?. Journal of Clinical Oncology, 2007, 25, 2632-2634.	1.6	6
119	Prevalence of BRCA1 and BRCA2 genomic rearrangements in a cohort of consecutive Italian breast and/or ovarian cancer families. Breast Cancer Research and Treatment, 2007, 106, 289-296.	2.5	27
120	A lymphotactin-producing monoclonal T-cell lymphoproliferative disorder with extreme lymphocytopenia and progressive leukoencephalopathy. Leukemia and Lymphoma, 2006, 47, 1421-1423.	1.3	5
121	Numb is a suppressor of Hedgehog signalling and targets Gli1 for Itch-dependent ubiquitination. Nature Cell Biology, 2006, 8, 1415-1423.	10.3	259
122	Improving the accuracy of BRCA1/2 mutation prediction: validation of the novel country-customized IC software. European Journal of Human Genetics, 2006, 14, 49-54.	2.8	16
123	BRCA1 and BRCA2: The genetic testing and the current management options for mutation carriers. Critical Reviews in Oncology/Hematology, 2006, 57, 1-23.	4.4	54
124	Novel BRCA1 and BRCA2 germline mutations and assessment of mutation spectrum and prevalence in Italian breast and/or ovarian cancer families. Breast Cancer Research and Treatment, 2006, 100, 83-91.	2.5	21
125	Thyroxine in Goiter,Helicobacter pyloriInfection, and Chronic Gastritis. New England Journal of Medicine, 2006, 354, 1787-1795.	27.0	284
126	MUC Gene Abnormalities in Sporadic and Hereditary Mucinous Colon Cancers with Microsatellite Instability. Disease Markers, 2005, 21, 121-126.	1.3	12

#	Article	IF	Citations
127	High Mobility Group A1 Is a Molecular Target for MYCN in Human Neuroblastoma. Cancer Research, 2005, 65, 8308-8316.	0.9	50
128	Genome-wide analysis of cAMP-response element binding protein occupancy, phosphorylation, and target gene activation in human tissues. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 4459-4464.	7.1	878
129	Dual role of the coactivator TORC2 in modulating hepatic glucose output and insulin signaling. Cell Metabolism, 2005, 2, 331-338.	16.2	65
130	Molecular mechanism of HMGA1 deregulation in human neuroblastoma. Cancer Letters, 2005, 228, 97-104.	7.2	29
131	Functional characterisation of the CRE/TATA box unit of type 2 deiodinase gene promoter in a human choriocarcinoma cell line. Journal of Molecular Endocrinology, 2004, 33, 51-58.	2.5	19
132	MRE11 expression is impaired in gastric cancer with microsatellite instability. Carcinogenesis, 2004, 25, 2337-2343.	2.8	46
133	Mutations of an intronic repeat induce impaired MRE11 expression in primary human cancer with microsatellite instability. Oncogene, 2004, 23, 2640-2647.	5.9	101
134	The CREB Coactivator TORC2 Functions as a Calcium- and cAMP-Sensitive Coincidence Detector. Cell, 2004, 119, 61-74.	28.9	581
135	New mutations and protein variants ofNBS1 are identified in cancer cell lines. Genes Chromosomes and Cancer, 2003, 36, 198-204.	2.8	15
136	EGFâ€•and cellâ€€cycleâ€“regulated STAG1/PMEPA1/ERG1.2 belongs to a conserved gene family and is overexpressed and amplified in breast and ovarian cancer. Molecular Carcinogenesis, 2003, 38, 188-200.	2.7	66
137	Attenuation of a phosphorylation-dependent activator by an HDACâ€“PP1 complex. Nature Structural and Molecular Biology, 2003, 10, 175-181.	8.2	179
138	TORCs. Molecular Cell, 2003, 12, 413-423.	9.7	564
139	Drug treatment in the development of mismatch repair defective acute leukemia and myelodysplastic syndrome. DNA Repair, 2003, 2, 547-559.	2.8	45
140	cAMP promotes pancreatic Î²-cell survival via CREB-mediated induction of IRS2. Genes and Development, 2003, 17, 1575-1580.	5.9	491
141	Human MRE11 is inactivated in mismatch repairâ€deficient cancers. EMBO Reports, 2002, 3, 248-254.	4.5	169
142	EGF Regulates a Complex Pattern of Gene Expression and Represses Smooth Muscle Differentiation during the Neurotypic Conversion of the Neural-Crest-Derived TC-1S Cell Line. Experimental Cell Research, 2001, 264, 353-362.	2.6	6
143	Thrombospondin-1 Is a Mediator of the Neurotypic Differentiation Induced by EGF in Thymic Epithelial Cells. Experimental Cell Research, 1999, 248, 79-86.	2.6	15
144	The growth arrest and downregulation of c-myc transcription induced by ceramide are related events dependent on p21 induction, Rb underphosphorylation and E2F sequestering. Cell Death and Differentiation, 1998, 5, 381-389.	11.2	43

#	Article	IF	Citations
145	Genomic characterization of the coding region of the human type II 5â€²-deiodinase gene. Molecular and Cellular Endocrinology, 1998, 141, 49-52.	3.2	37
146	2-Aminopurine Unravels a Role for pRB in the Regulation of Gene Expression by Transforming Growth Factor Î². Journal of Biological Chemistry, 1997, 272, 5313-5319.	3.4	6
147	Activation of Three Distinct RXR/RAR Heterodimers Induces Growth Arrest and Differentiation of Neuroblastoma Cells. Journal of Biological Chemistry, 1997, 272, 26693-26701.	3.4	48
148	cDNA cloning reveals a tissue specific expression of alternatively spliced transcripts of the ryanodine receptor type 3 (RyR3) calcium release channel. FEBS Letters, 1996, 394, 76-82.	2.8	41
149	High plasma levels of endothelin-1 in untreated Addison's disease. European Journal of Endocrinology, 1996, 135, 696-699.	3.7	6
150	Molecular structure and tissue distribution of ryanodine receptors calcium channels. Medicinal Research Reviews, 1995, 15, 313-323.	10.5	49
151	5FU/Oxaliplatin-Induced Jagged1 Cleavage Counteracts Apoptosis Induction in Colorectal Cancer: A Novel Mechanism of Intrinsic Drug Resistance. Frontiers in Oncology, 0, 12, .	2.8	2